Tirzepatide's Patent Cliff: A Decade Behind Semaglutide, and Built Differently

A Decade of Runway, By Design

Semaglutide’s foundational compound patent was filed in March 2006 and, examined in detail elsewhere in this issue, has already begun lapsing across major markets as of March 2026. Tirzepatide’s core composition-of-matter patent does not expire until January 5, 2036 — a full decade later, and the gap is not a coincidence or a quirk of different patent offices. Tirzepatide is simply a newer molecule, filed and granted years after semaglutide, first approved for type 2 diabetes in 2022 as Mounjaro and for chronic weight management in November 2023 as Zepbound. A younger patent, filed later, expires later, on the same standard twenty-year clock that governed semaglutide’s own foundational protection.

That decade of additional runway is, on its own, one of the more underappreciated strategic assets in Eli Lilly’s current portfolio. It means Lilly gets to observe, in granular real-world detail, exactly how Novo’s cliff plays out — which secondary patents actually held up under challenge, which markets moved fastest to generic entry, how compounding pharmacies and regulators interacted once shortage-based exemptions started closing — and adjust its own defensive patent strategy accordingly, years before facing the equivalent pressure itself.

The Thicket Being Built in Real Time

Lilly is not waiting until the mid-2030s to start building that defense. As of the most recent public patent tracking, the company has filed roughly 53 US patent applications and been granted 16 patents covering tirzepatide across its two branded products — a considerably smaller portfolio than semaglutide’s 320 filed and 154 granted, but tirzepatide is also considerably earlier in its commercial life, having only launched in 2022, versus semaglutide’s first approval back in 2017. The trajectory, not the current count, is the signal worth watching: Lilly is building its own version of Novo’s thicket, and it has roughly a decade longer to do it in before the core patent actually matters.

Two specific composition-of-matter patents anchor the current picture: US Patent No. 9,573,969, set to expire in September 2031, and US Patent No. 10,533,037, set to expire in January 2037 — illustrating a point worth making explicit, since it applies just as much to semaglutide’s cliff as to tirzepatide’s. A drug’s patent protection is very rarely a single date. It is a portfolio of overlapping patents with different filing dates, different expiration dates, and different scope, and the honest answer to "when does the patent expire" is almost always "which patent, and for which specific claim."

The 2036-to-2041 Corridor

The figure most consistently cited across patent-tracking sources for tirzepatide’s core molecule protection is January 2036. Beyond that core patent, a set of follow-on patents covering formulations, delivery devices, and specific methods of treatment are expected to extend meaningful commercial protection to roughly 2041, with some device-specific and pediatric-exclusivity-linked protections potentially running later still. That five-year gap between core molecule expiration and full generic freedom mirrors, almost exactly in structure if not in specific years, the pattern already playing out with semaglutide’s own compound-patent-versus-secondary-patent gap — evidence that this has become the standard defensive architecture for the entire GLP-1 category, not an idiosyncrasy of either company.

It is worth flagging that some patent-analytics services have floated considerably earlier "potential generic entry" dates for specific tirzepatide patents — estimates in the 2027 to 2028 range appear in some automated patent-tracking analyses. Those figures typically reflect the earliest date a specific, narrower patent within the broader thicket becomes legally challengeable, not a realistic date for full, unrestricted generic tirzepatide reaching the market. The weight of analysis across patent law specialists, pharma-industry trackers, and the companies’ own securities disclosures converges on 2036 as the meaningful date for the core molecule, with the 2041 corridor as the more realistic date for genuinely unrestricted competition. Investors should treat any considerably earlier date with real skepticism unless it comes with a specific, named patent and a specific, credible legal theory attached.

Learning From the Playbook Being Written Next Door

The single most useful thing Lilly gets from its ten-year head start is not legal — it is observational. Merck’s defense of Keytruda’s 2028 cliff, examined in detail elsewhere in this issue, follows a three-track playbook: reformulation into a subcutaneous product with independently patentable exclusivity, fixed-dose combinations that extend meaningful protection on specific regimens well past the core patent, and aggressive pipeline diversification to build revenue that does not depend on the original molecule at all. Novo’s own semaglutide defense leans hard on the same reformulation and secondary-patent logic. There is no reason to expect Lilly’s eventual tirzepatide defense will look meaningfully different in structure — a next-generation delivery device, a fixed-dose combination with a complementary mechanism, and continued pipeline investment in the successor molecules, retatrutide chief among them, discussed at length elsewhere in this issue, that are explicitly designed to obsolete tirzepatide commercially well before its patent cliff would otherwise force the issue.

That last point deserves real emphasis, because it is specific to this category in a way that does not apply to Keytruda’s cliff. Merck does not have an obviously superior internal successor to pembrolizumab waiting in the wings; its defense is built substantially on assets acquired or licensed from elsewhere. Lilly, by contrast, already has retatrutide — a molecule the company’s own Phase 3 data suggests is meaningfully more effective than tirzepatide — advancing through late-stage trials right now. If retatrutide reaches approval and captures a meaningful share of the cardiometabolic market before 2036, tirzepatide’s eventual patent cliff may end up mattering considerably less commercially than the cliff date alone would suggest, because Lilly may have already migrated much of its own patient base to a newer, still-protected molecule by the time generic tirzepatide becomes a real threat.

The Same Compounding Dynamic, on the Same Legal Basis

Tirzepatide has followed the identical compounding pattern already described for semaglutide, and the underlying legal mechanism is the same: the drug sat on the FDA’s shortage list for an extended period following its 2022 launch, triggering the same Section 503A exemption that allowed compounding pharmacies to legally prepare copies during the shortage, entirely independent of the underlying patents remaining fully enforceable. As of April 2026, no FDA-approved generic tirzepatide exists in the US market, and none will until the patents expire between 2034 and 2036 on most published timelines — the compounded versions that filled the supply gap during the shortage period are a separate, temporary phenomenon tied to manufacturing capacity, not an early preview of genuine post-patent generic competition.

Why the Extra Five to Ten Years Matters More Than It Sounds

It would be easy to read tirzepatide’s later cliff as simply "the same story as semaglutide, delayed" — but the gap changes the competitive dynamics in ways worth spelling out. By the time tirzepatide’s core patent lapses in 2036, the GLP-1 category itself will likely look nothing like it does today. Oral small-molecule GLP-1 therapy, discussed elsewhere in this issue in the context of Lilly’s own Foundayo, will be a full decade into commercial maturity by 2036, not a novel 2026 launch. Triple agonists in retatrutide’s class may themselves be facing their own follow-on competition by then. A patent cliff that would have been a defining commercial event if it arrived on semaglutide’s 2026-to-2032 timeline may, by 2036, be a comparatively minor event for a molecule that has already been substantially superseded by its own manufacturer’s newer products — a dynamic that has no real precedent in the semaglutide story, where Novo does not yet have an obviously superior successor molecule of its own in late-stage trials to the same degree Lilly does with retatrutide.

The Investment Read

For a venture investor, tirzepatide’s cliff is less an near-term opportunity than a long-horizon planning input. The manufacturing infrastructure thesis discussed elsewhere in this issue — India’s CDMO sector building peptide and sterile fill-finish capacity ahead of GLP-1 volume growth — applies to tirzepatide’s eventual generic wave just as it applies to semaglutide’s current one, but on a decade-longer timeline, which changes the calculus for how early a manufacturing-capacity bet needs to be placed relative to the eventual payoff. The more immediate, actionable read is competitive rather than generic-manufacturing-related: any company building a next-generation obesity or diabetes therapeutic has to underwrite its own commercial window against a Lilly product that will remain fully patent-protected, and defended by an increasingly dense thicket, for at least another decade — a considerably longer moat than most venture-stage competitors in this category are currently pricing in.

Two Cliffs, One Category, Different Shapes

Read alongside semaglutide’s own cliff, the tirzepatide story is the clearer illustration of a pattern that will keep repeating across this category for the next fifteen years: patent cliffs in modern biologics and peptide therapeutics are not single events with single dates, they are staggered unlockings shaped by filing dates, jurisdiction-specific extension mechanics, and secondary patent thickets that originators actively build in real time, learning from whichever competitor’s cliff happened to arrive first. Novo is living through that process right now. Lilly has the considerably more comfortable position of watching, learning, and building its own defense a decade ahead of needing it — and it is already doing exactly that.